Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @mkaeberlein
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @mkaeberlein
-
Matt Kaeberlein proslijedio/la je Tweet
#MeetTheEditors reviewing articles for our Special Issue on aging, geroscience and longevity, alongside@jesstylerlab and@mkaeberlein https://elifesciences.org/inside-elife/42ef20dc/special-issue-meet-the-editors-for-aging-geroscience-and-longevity?utm_source=twitter&utm_medium=social …pic.twitter.com/DkiuDfTMuh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
I don't know for sure that
#rapamycin will help Alzheimer's disease patients, but if someone I loved was diagnosed, I would move move heaven and earth to get them on it as early as possible. It's deeply disappointing that this hasn't been tested yet.https://twitter.com/johnmsmart/status/1224093641142161408 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Matt Kaeberlein proslijedio/la je Tweet
Our work was published regarding loss of acidity in the yeast lysosome-like vacuole resulting in age-associated iron sulfur cluster defects. Lots of hard work by many amazing people.
@mkaeberlein@crane_mm@UHCL#UHCL#mitochondria#lysosome#gerosciencehttps://link.springer.com/article/10.1007/s11357-020-00159-3 …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Matt Kaeberlein proslijedio/la je Tweet
Innovative peer review is one of the reasons Senior Editor Jess Tyler encourages her colleagues to submit to eLife. Read the #CallforPapers for our latest Special Issue on aging research, which Jess is leading alongside Reviewing Editor@mkaeberlein https://elifesciences.org/inside-elife/4f706531/special-issue-call-for-papers-in-aging-geroscience-and-longevity …pic.twitter.com/gloYpCZTRgHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Matt Kaeberlein proslijedio/la je Tweet
Have you nominated your pup for the
@DogAgingProject?@Dubs is doing his part! A@UWBiology professor is spearheading the effort to improve our understanding of how#dogs age: https://magazine.washington.edu/feature/how-does-aging-affect-dogs-study-recruiting-thousands-to-find-out/ …pic.twitter.com/FnWHDCVw59
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Matt Kaeberlein proslijedio/la je Tweet
In conclusion: preprint; cite preprints; and don't be a jerk.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
I've learned enough about biological complexity to never claim with certainty what will or won't happen in an experiment. Those who do so demonstrate their own ignorance. My informed guess is that
#mTOR inhibitors will be clinically useful at combatting aging in humans.https://twitter.com/JuliaB_fitness/status/1219721791960244225 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Agreed. And I'd add that the reduction in respiratory infections is perhaps more impactful. I forget the numbers, but I recall the potential if extended to the general population was quite large in terms of elderly deaths and healthcare cost.https://twitter.com/davidjglassMD/status/1218742845575716866 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Pan Zheng's group proposed rejuvenation of hematopoietic stem cells in their IMO greatly underappreciated 2009 paper (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020596/ …), although mechanism is unknown. My current guess is that rapa suppresses p16-mediated inflammation (SASP) which impairs immune function.https://twitter.com/topologic_apple/status/1218662151277117440 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Matt Kaeberlein proslijedio/la je Tweet
The
#mTOR hypothesis of aging is still alive but our work and others show that we need to find better ways of selectively inhibiting mTORC1, and avoid inhibiting mTORC2 or other kinases that are necessary for health and survivalHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Two RCTs with a rapamycin derivative showed significant improvement in immune function in elderly humans. The only RCT that failed was when they left out the rapamycin derivative. Good to maintain healthy skepticism, but don't ignore the data. More rapa RCTs are coming.https://twitter.com/JuliaB_fitness/status/1218694797122318337 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Matt Kaeberlein proslijedio/la je Tweet
When a rapalog was used, there was a reproducible improvement in humans, and a decrease in immune senescence; the recent failure was with a kinase inhibitor of mTOR, which also inhibits mTORC2 and likely PI3 kinase.
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
I suppose, if you want to call up to 60% increase in life expectancy (~2 decades human:mouse equivalent) "a little". Oh, and improved functioning of heart, immune, brain, kidney, intestine, peridontium, ...https://twitter.com/JuliaB_fitness/status/1218627384028663808 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
I agree completely. Most of my colleagues are rigorous scientists and would be very cautious about making recommendations that the public should start taking drugs or supplements based on anecdotal, uncontrolled self-experimentation.https://twitter.com/shunyata2000/status/1218623281672024064 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At least a dozen from multiple independent groups. There are many good reviews on this topic from myself,
@LammingLab, and@DMSabatini among others. You can start with refs 15-28 here: https://www.sciencedirect.com/science/article/pii/S246850112030002X?via%3Dihub …https://twitter.com/JuliaB_fitness/status/1218604349259231233 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Well, as someone who knows at least a little bit about the field, I have to disagree. Pretty sure the "mTOR
#antiaging hypothesis in humans" is alive and well.https://twitter.com/JuliaB_fitness/status/1218564674045861893 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In a perfect world with unlimited resources (not realistic I know), I would use rapamycin alone and perhaps also rapa + RTB101. Would also want to go beyond immune to other indications such as heart and cognitive function, periodontal disease, etc. where rapa may be effective.https://twitter.com/johndotuk/status/1218560445499551746 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
I disagree with your premise. We obviously don't know yet in people, but the data for functional rejuvenation by rapamycin in mice is more extensive, more robust, and (at least so far) more reproducible than for any other intervention.https://twitter.com/JuliaB_fitness/status/1218554237820514306 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Matt Kaeberlein proslijedio/la je Tweet
Our paper on senescence-based biomarkers of aging is now published in
#PLOSBiology !! 'A proteomic atlas of senescence-associated secretomes for aging biomarker development' (https://dx.plos.org/10.1371/journal.pbio.3000599 …)@birgits61642917@kaleabhijit#livebetterlongerHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
My thoughts on the unsuccessful PROTECTOR1 trial of RTB101 by resTORbio. As always, discussion and constructive criticisms/comments welcome.https://www.sciencedirect.com/science/article/pii/S246850112030002X?via%3Dihub …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.